Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Circulation ; 111(7): 863-70, 2005 Feb 22.
Artículo en Inglés | MEDLINE | ID: mdl-15699251

RESUMEN

BACKGROUND: Tumor necrosis factor alpha-alpha (TNF-alpha) activation is an independent prognostic indicator of mortality in patients with heart failure (HF). Despite the recognition that several TNF family cytokines are elevated during myocardial infarction, their role in predicting subsequent prognosis in these setting remains poorly understood. METHODS AND RESULTS: We performed a systematic evaluation of TNF-alpha and its type 1 and 2 soluble receptors, together with interleukin (IL)-6, IL-1 receptor antagonist, and IL-10, in 184 patients (132 men; mean age, 64+/-12) consecutively admitted for myocardial infarction. We correlated their values to short- and long-term incidence of death and HF (primary outcome). In 10 patients, we also studied the presence of transcardiac gradients for TNF-alpha and its soluble receptors. The control group comprised 45 healthy subjects who were sex and age matched (33 men; mean age, 65+/-6 years) to the patients. All tested cytokines were increased in patients, and no transcardiac or systemic AV difference was found. After a median follow-up of 406 days (range, 346 to 696 days), 24 patients died and 32 developed HF. Univariate analysis showed that all cytokines were related to outcome, whereas after adjustment for baseline and clinical characteristics, sTNFR-1 remained the only independent predictor of death and HF (hazard ratio, 2.9; 95% CI, 1.9 to 3.8, tertile 1 versus 3), together with left ventricular ejection fraction, Killip class, and creatine kinase-MB at peak. CONCLUSIONS: sTNFR-1 is a major short- and long-term predictor of mortality and HF in patients with acute myocardial infarction.


Asunto(s)
Insuficiencia Cardíaca/sangre , Infarto del Miocardio/sangre , Infarto del Miocardio/mortalidad , Valor Predictivo de las Pruebas , Receptores del Factor de Necrosis Tumoral/sangre , Anciano , Anciano de 80 o más Años , Análisis de Varianza , Estudios de Casos y Controles , Creatina Quinasa/sangre , Citocinas/sangre , Femenino , Estudios de Seguimiento , Humanos , Masculino , Persona de Mediana Edad , Pronóstico , Solubilidad , Volumen Sistólico , Análisis de Supervivencia
2.
Circulation ; 107(2): 264-70, 2003 Jan 21.
Artículo en Inglés | MEDLINE | ID: mdl-12538426

RESUMEN

BACKGROUND: Endothelial apoptosis of atherosclerotic lesions is a possible determinant for the stable-to-vulnerable plaque transition. Recent data support the notion that plaque activation may be a pan-coronary process, advocating the existence of circulating triggers. METHODS AND RESULTS: Serum from 40 healthy subjects (group 1) and 73 patients with stable angina (n=32; group 2) or acute coronary syndromes (n=41; group 3) was incubated with human umbilical vein endothelial cells. The percentage of apoptosis by flow cytometry and Fas, Bax, and Bcl-2 protein expression by immunoblotting were evaluated at entry in patients and control subjects and repeated after 12 months in group 3. At baseline, apoptotic nuclei were higher in group 3 (14+/-6%) than in group 2 (3.3+/-1.8%) and group 1 (1.35+/-0.8%) (P<0.001). Fas and Bcl-2 were increased in group 3 with respect to groups 1 and 2 (P<0.01). Coincubation of group 3 serum with anti-tumor necrosis factor-alpha and anti-interleukin-6 monoclonal antibodies did not affect the human umbilical vein endothelial cell apoptotic process, whereas addition of Trolox decreased apoptosis to <50%. The percentage of apoptosis in group 3 significantly correlated to the numbers of coronary complex lesions at angiography (r=0.58, P<0.0005). In group 3, apoptosis and the Bax/Bcl-2 ratio decreased at 1 year (P<0.0001, P<0.05 respectively). CONCLUSIONS: Serum from patients with acute coronary syndromes displays a proapoptotic effect on human endothelial cells, supporting the theory of the existence of circulating triggers potentially able to activate atherosclerotic lesions.


Asunto(s)
Apoptosis/efectos de los fármacos , Proteínas Sanguíneas/farmacología , Enfermedad Coronaria/sangre , Endotelio Vascular/efectos de los fármacos , Enfermedad Aguda , Anciano , Angina de Pecho/sangre , Angina de Pecho/diagnóstico , Anticuerpos Monoclonales/farmacología , Antígenos CD/sangre , Antioxidantes/farmacología , Células Cultivadas , Cromanos/farmacología , Angiografía Coronaria , Enfermedad Coronaria/diagnóstico , Endotelio Vascular/citología , Endotelio Vascular/metabolismo , Femenino , Humanos , Proteína Antagonista del Receptor de Interleucina 1 , Interleucina-6/antagonistas & inhibidores , Interleucina-6/sangre , Lipoproteínas LDL/sangre , Masculino , Persona de Mediana Edad , Proteínas Proto-Oncogénicas/biosíntesis , Proteínas Proto-Oncogénicas c-bcl-2/biosíntesis , Receptores del Factor de Necrosis Tumoral/sangre , Receptores Tipo I de Factores de Necrosis Tumoral , Receptores Tipo II del Factor de Necrosis Tumoral , Sialoglicoproteínas/sangre , Factor de Necrosis Tumoral alfa/análisis , Factor de Necrosis Tumoral alfa/antagonistas & inhibidores , Proteína X Asociada a bcl-2 , Receptor fas/biosíntesis
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA